Myeloma Center

You are here

Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.

TitlePomalidomide: new immunomodulatory agent with potent antiproliferative effects.
Publication TypeJournal Article
Year of Publication2013
AuthorsRichardson PG, Mark TM, Lacy MQ
JournalCrit Rev Oncol Hematol
Volume88 Suppl 1
PaginationS36-44
Date Published2013 Oct
ISSN1879-0461
KeywordsAntineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Cell Proliferation, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Dexamethasone, Humans, Immunologic Factors, Multiple Myeloma, Thalidomide
Abstract

New treatment options are urgently needed for patients with relapsed multiple myeloma (MM) who are refractory to thalidomide, lenalidomide, and bortezomib therapy. Pomalidomide, a second-generation immunomodulatory agent, has been shown to exert direct antiproliferative actions on MM cells, effects on the bone-marrow microenvironment, and immunomodulation. In phase I clinical trials, pomalidomide has demonstrated promising response rates in patients with relapsed and/or refractory MM, with manageable toxicity. In phase II trials pomalidomide, 2-4 mg/daily, given continuously or on days 1-21 of a 28-day cycle, in combination with dexamethasone, has been associated with high quality and durable clinical responses in patients who are refractory to lenalidomide, bortezomib, or both. Pomalidomide appears to be well tolerated; hematologic toxicities are the most commonly reported adverse events and peripheral neuropathy is rare. Phase III trials are currently underway to determine the optimal dose and combination regimen of pomalidomide in the treatment of MM.

DOI10.1016/j.critrevonc.2013.02.001
Alternate JournalCrit. Rev. Oncol. Hematol.
PubMed ID23786844